T2Biosystems Announces Strategic Investment with In-Q-Tel

[CC-Conrad Clyburn-MedForeSight]

As reported in BioSpace, T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance (MR) technology, today announced a strategic investment and technology advancement agreement with In-Q-Tel, the independent strategic investment firm. T2 Biosystems’ technology has been validated in multiple published journal articles and has shown to accurately analyze viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets. The In-Q-Tel investment is also part of a $10.8 million Series B funding round, with additional participation by Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners and Partners Healthcare.